A new approach to the clinical subclassification of heart failure with preserved ejection fraction

被引:20
|
作者
Nouraei, Hirmand [1 ]
Rabkin, Simon W. [1 ]
机构
[1] Univ British Columbia, Dept Med, Div Cardiol, Vancouver, BC, Canada
关键词
Heart failure; Preserved ejection fraction; Unsupervised machine learning; Cluster analysis; CORONARY-ARTERY-DISEASE; ALGORITHM;
D O I
10.1016/j.ijcard.2021.01.052
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Heart failure with preserved ejection (HFpEF) represents nearly half of all patients with heart failure (HF). The objective of this study was to determine whether patient characteristics identify discrete kinds of HFpEF. Methods: Data were collected on 196 patients with HFpEF in a non-hospitalized setting. Clinical and laboratory variables were collected, and 47 candidate variables were examined by the unsupervised clustering strategy partitioning around medoids. The Meta-analysis Global Group in Chronic Heart Failure (MAGGIC) risk score was calculated. Follow-up data on all-cause mortality, cardiovascular mortality, and HF exacerbation, were collected and were not part of the data used to identify subgroups. Results: Six significantly different groups or clusters were found. There were three groups of women (i) individuals with a low proportion of vascular risk factors (HFpEF(1)) (ii) individuals with a high proportion of hypertension and diabetes, but lower proportion of kidney disease and diastolic dysfunction (HFpEF(3)) (iii) older individuals with high rates of atrial fibrillation (AF), chronic kidney disease. They had the worst longterm outcomes (HFpEF(4)). There were three groups of men (i) individuals with a high proportion of coronary artery disease (CAD), dyslipidemia, higher serum creatinine, and diastolic dysfunction (HFpEF(2)) (ii) individuals with highest BMI, and high proportion of CAD, obstructive sleep apnea, and poorly controlled diabetes (HFpEF(5)) (iii) individuals with high rates of AF, elevated BNP, biventricular remodeling (HFpEF(6)). They had a high cardiovascular mortality. Conclusions: HFpEF consists of a heterogenous group of individuals with six distinct clinical subsets that have different long-term outcomes. (C) 2021 Elsevier B.V. All rights reserved.
引用
收藏
页码:138 / 143
页数:6
相关论文
共 50 条
  • [41] Current Therapeutic Approach in Heart Failure with Preserved Ejection Fraction
    Nativi-Nicolau, Jose
    Ryan, John J.
    Fang, James C.
    [J]. HEART FAILURE CLINICS, 2014, 10 (03) : 525 - +
  • [42] Epidemiology and clinical course of heart failure with preserved ejection fraction
    Lam, Carolyn S. P.
    Donal, Erwan
    Kraigher-Krainer, Elisabeth
    Vasan, Ramachandran S.
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2011, 13 (01) : 18 - 28
  • [43] Epidemiological and clinical boundaries of heart failure with preserved ejection fraction
    Gentile, Francesco
    Ghionzoli, Nicolo
    Borrelli, Chiara
    Vergaro, Giuseppe
    Pastore, Maria Concetta
    Cameli, Matteo
    Emdin, Michele
    Passino, Claudio
    Giannoni, Alberto
    [J]. EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2022, 29 (08) : 1233 - 1243
  • [44] Clinical and electrocardiographic features of heart failure with preserved ejection fraction
    Azaiez, M. A. Mohamed Ali
    Hamdi, S.
    Elhraiech, A.
    Chakroun, M.
    Jomaa, W.
    Ben Hamda, K.
    Maatouk, F.
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2015, 17 : 152 - 152
  • [45] Epidemiology and Clinical Features of Heart Failure with Preserved Ejection Fraction
    Teramoto, Kanako
    Teng, Tiew-Hwa Katherine
    Chandramouli, Chanchal
    Tromp, Jasper
    Sakata, Yasuhiko
    Lam, Carolyn S. P.
    [J]. CARDIAC FAILURE REVIEW, 2022, 8
  • [46] Transitioning from Preclinical to Clinical Heart Failure with Preserved Ejection Fraction: A Mechanistic Approach
    Bayes-Genis, Antoni
    Bisbal, Felipe
    Nunez, Julio
    Santas, Enrique
    Lupon, Josep
    Rossignol, Patrick
    Paulus, Walter
    [J]. JOURNAL OF CLINICAL MEDICINE, 2020, 9 (04)
  • [47] New therapy concepts for heart failure with preserved ejection fraction
    Tschoepe, C.
    Pieske, B.
    [J]. HERZ, 2015, 40 (02) : 194 - +
  • [48] New Drugs and Devices in the Pipeline for Heart Failure with Reduced Ejection Fraction Versus Heart Failure with Preserved Ejection Fraction
    Raina A.
    Kanwar M.
    [J]. Current Heart Failure Reports, 2014, 11 (4) : 374 - 381
  • [49] New therapies for the treatment of heart failure with preserved ejection fraction
    Meier, Mackenzi L.
    Pierce, Kristen N.
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2022, 79 (17) : 1424 - 1430
  • [50] New Treatment Strategy for Heart Failure with Preserved Ejection Fraction
    Yamamoto, Kazuhiro
    Mano, Toshiaki
    Sakata, Yasushi
    Ohtani, Tomohito
    Takeda, Yasuharu
    Komuro, Issei
    [J]. JOURNAL OF CARDIAC FAILURE, 2011, 17 (09) : S125 - S125